SCHEMBL1482722

SCHEMBL1482722

COc1cc(Cl)ccc1-c1nc2cc(F)c(F)cc2n1CC1CCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.49
ALOX5 P09917 2/20 0.48
CRHR1 P34998 6/20 0.42
KCNH2 Q12809 3/20 0.40
VDR P11473 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTGER4 P35408 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
SLC6A4 P31645 1/20 0.37
GHSR Q92847 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482662 0.99 NR1H4 (0.51) NR1H4ALOX5CRHR1KCNH2VDR
SCHEMBL1482505 0.91 ALOX5 (0.44) NR1H4ALOX5CRHR1CYP3A4CYP2C9
SCHEMBL1482483 0.89 NR1H4 (0.42) NR1H4ALOX5CRHR1KCNH2CYP11B1
SCHEMBL1482100 0.88 NR1H4 (0.50) NR1H4ALOX5KCNH2VDRCYP11B1
SCHEMBL1482697 0.88 NR1H4 (0.50) NR1H4ALOX5KCNH2VDRCYP11B1
SCHEMBL1482738 0.88 HTR2C (0.42) NR1H4ALOX5CRHR1GRIN2BCYP11B1
SCHEMBL1483132 0.87 NR1H4 (0.49) NR1H4ALOX5KCNH2VDRCYP11B1
SCHEMBL1482243 0.87 NR1H4 (0.47) NR1H4ALOX5CRHR1KCNH2VDR
SCHEMBL1482402 0.85 LMNA (0.45) NR1H4ALOX5VDRGRIN1GRIN2B
SCHEMBL1482812 0.85 NR1H4 (0.54) NR1H4ALOX5KCNH2VDRPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 NR1H4 776/4885ALOX5 3919/4885CRHR1 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.